

Hepatitis¹

Base de Datos Medline. Búsqueda hasta Marzo 2005, artículos de revisión (review papers).

1. Locarnini S. Therapies for hepatitis B: where to from here? *Gastroenterology* 2005;128(3):789-92.
2. [No authors listed]. Advising patients with hepatitis C in primary care. *Drug Ther Bull* 2005;43(3):22-4.
3. Cooper CL. Therapies for HIV and viral hepatitis coinfection. *Expert Rev Anti Infect Ther* 2005;3(1):81-9.
4. Bhopale GM, Nanda RK. Prospects for hepatitis C vaccine. *Acta Virol* 2004; 48(4):215-21.
5. Daniel S. Chronic hepatitis C treatment patterns in African American patients: an update. *Am J Gastroenterol* 2005;100(3):716-22.
6. Castera L, Chouteau P, Hezode C, Zafrani ES, Dhumeaux D, Pawlotsky JM. Hepatitis C virus-induced hepatocellular steatosis. *Am J Gastroenterol* 2005; 100(3):711-5.
7. Zhang FK, Zhang JY, Jia JD. Treatment of patients with alcoholic liver disease. *Hepatobiliary Pancreat Dis Int* 2005;4(1):12-7.
8. Vergani D, Mieli-Vergani G. Autoimmune hepatitis. *Minerva Gastroenterol Dietol* 2004;50(2):113-23.
9. Schaefer S. Hepatitis B virus: significance of genotypes. *J Viral Hepat* 2005; 12(2):111-24.
10. Van Damme PA, Van Herck K, Banatvala JE. Do we need hepatitis A booster vaccinations? *J Travel Med* 2004;11(3):179-80.
11. Triantos C, Samonakis D, Stigliano R, Thalheimer U, Patch D, Burroughs A. Liver transplantation and hepatitis C virus: systematic review of antiviral therapy. *Transplantation* 2005;79(3):261-8.
12. van Hoek B. Non-alcoholic fatty liver disease: a brief review. *Scand J Gastroenterol Suppl* 2004;(241):56-9.
13. Buster EH, van der Eijk AA, de Man RA, Schalm SW. Doctor-to-patient transmission of hepatitis B virus: the potential of antiviral therapy for prevention. *Scand J Gastroenterol Suppl* 2004;(241):45-9.
14. Barry J, Bourke M, Buckley M, Coughlan B, Crowley D, Cullen W, Dooley S, Keating S, Kelleher D, Moloney J, Murray F, McCormick PA, MacMathuna P, O'Connor J, O'Grady J, O'Sullivan C, O'Sullivan P, Quinn C, Smyth B, Sweeney B; Dublin Area Hepatitis C Initiative Group. Hepatitis C among drug users: consensus guidelines on management in general practice. *Ir J Med Sci* 2004; 173(3):145-50.
15. Czaja AJ, Bianchi FB, Carpenter HA, Krawitt EL, Lohse AW, Manns MP, McFarlane IG, Mieli-Vergani G, Toda G, Vergani D, Vierling J, Zeniya M. Treatment challenges and investigational opportunities in autoimmune hepatitis. *Hepatology* 2005;41(1):207-15.
16. Feld JJ, Liang TJ. HCV persistence: cure is still a four letter word. *Hepatology* 2005;41(1):23-5.
17. Rawls RA, Vega KJ. Viral hepatitis in minority America. *J Clin Gastroenterol* 2005;39(2):144-51.
18. Thomson BJ, Finch RG. Hepatitis C virus infection. *Clin Microbiol Infect.* 2005;11(2):86-94.
19. Niro GA, Rosina F, Rizzetto M. Treatment of hepatitis D. *J Viral Hepat* 2005; 12(1):2-9.
20. Neumann-Haefelin C, Blum HE, Chisari FV, Thimme R. T cell response in hepatitis C virus infection. *J Clin Virol* 2005;32(2):75-85.
21. Siddiqi K. Hepatitis B (prevention). *Clin Evid* 2004;(11):979-94.
22. Nunez M, Soriano V. Hepatotoxicity of anti-retrovirals: incidence, mechanisms and management. *Drug Saf* 2005;28(1):53-66.

¹ En colaboración con la Biblioteca Médica Nacional, UNAH (<http://cidbimena.desastres.hn>), y el Comité Consultivo de la Biblioteca Virtual en Salud de Honduras (<http://www.bvs.hn>).

23. Atkins M, Nolan M. Sexual transmission of hepatitis B. *Curr Opin Infect Dis* 2005;18(1):67-72.
24. Bianco E, De Masi S, Mele A, Jefferson T. Effectiveness of immune globulins in preventing infectious hepatitis and hepatitis A: a systematic review. *Dig Liver Dis* 2004;36(12):834-42.
25. White FV, Dehner LP. Viral diseases of the liver in children: diagnostic and differential diagnostic considerations. *Pediatr Dev Pathol* 2004;7(6):552-67.
26. Poland GA, Jacobson RM. Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. *N Engl J Med* 2004;351(27):2832-8. Erratum in: *N Engl J Med* 2005;352(7):740.
27. Gheorghe L, Iacob S, Popescu I. Living donor liver transplantation and hepatitis C. *Rom J Gastroenterol* 2004;13(4):317-27.
28. Ramesh S, Sanyal AJ. Hepatitis C and nonalcoholic fatty liver disease. *Semin Liver Dis* 2004;24(4):399-413.
29. Suriawinata A, Fiel MI. Liver pathology in obesity. *Semin Liver Dis* 2004; 24(4):363-70.
30. Choudhury J, Sanyal AJ. Clinical aspects of fatty liver disease. *Semin Liver Dis* 2004;24(4):349-62.
31. Sherman M, Bain V, Villeneuve JP, Myers RP, Cooper C, Martin S, Lowe C. The management of chronic viral hepatitis: a Canadian consensus conference 2004. *Can J Gastroenterol* 2004;18(12):715-28.
32. Mohanty SR, Cotler SJ. Management of hepatitis B in liver transplant patients. *J Clin Gastroenterol* 2005;39(1):58-63.
33. Nanda K. Non-alcoholic steatohepatitis in children. *Pediatr Transplant* 2004; 8(6):613-8.
34. Vergani D, Mieli-Vergani G. Mechanisms of autoimmune hepatitis. *Pediatr Transplant* 2004;8(6):589-93.
35. Practice Committee of the American Society for Reproductive Medicine. Hepatitis and reproduction. *Fertil Steril* 2004;82(6):1754-64.
36. Ferenci P. Treatment of chronic viral hepatitis. *Best Pract Res Clin Gastroenterol* 2004;18 Suppl:113-20.
37. Sehgal S, Jackson Allen PL. Hepatitis C in children. *Pediatr Nurs* 2004; 30(5):409-13.
38. Bruss V. Envelopment of the hepatitis B virus nucleocapsid. *Virus Res* 2004; 106(2):199-209.
39. Moradpour D, Blum HE. A primer on the molecular virology of hepatitis C. *Liver Int* 2004;24(6):519-25.
40. Siddiqi K. Hepatitis B. *Clin Evid* 2003;(10):852-66. Update in: *Clin Evid* 2004;(11):979-94.
41. Jones EA. Fatigue complicating chronic liver disease. *Metab Brain Dis* 2004;19(3-4):421-9.
42. Forton DM, Thomas HC, Taylor-Robinson SD. Central nervous system involvement in hepatitis C virus infection. *Metab Brain Dis* 2004;19(3-4):383-91.
43. Sene D, Limal N, Cacoub P. Hepatitis C virus-associated extrahepatic manifestations: a review. *Metab Brain Dis* 2004;19(3-4):357-81.
44. Tillmann HL. Hepatitis C virus infection and the brain. *Metab Brain Dis* 2004; 19(3-4):351-6.
45. Bouchard MJ, Schneider RJ. The enigmatic X gene of hepatitis B virus. *J Virol* 2004;78(23):12725-34.
46. Neuman MG. Cytokines--central factors in alcoholic liver disease. *Alcohol Res Health* 2003;27(4):307-16.
47. Schiff ER, Ozden N. Hepatitis C and alcohol. *Alcohol Res Health* 2003; 27(3):232-9.
48. Locarnini S, Hatzakis A, Heathcote J, Keeffe EB, Liang TJ, Mutimer D, Pawlotsky JM, Zoulim F. Management of antiviral resistance in patients with chronic hepatitis B. *Antivir Ther* 2004;9(5):679-93.
49. Olteanu D, Argesanu M, Radu L, Nestor D, Bratanescu S, Lupu D. Extrahepatic manifestations in hepatitis C virus infection. *Rom J Intern Med* 2004;42(1):69-81.
50. Mateescu RB, Rimbas M, Voiosu R. The immunopathogenesis of viral hepatitis. *Rom J Intern Med* 2004;42(1):59-67.
51. Voiosu R. The treatment of chronic hepatitis B. *Rom J Intern Med* 2000-2001; 38-39:21-31.
52. Aggarwal R, Ranjan P. Preventing and treating hepatitis B infection. *BMJ* 2004; 329(7474):1080-6.
53. Aspinall RJ, Pockros PJ. The management of side-effects during therapy for hepatitis C. *Aliment Pharmacol Ther* 2004;20(9):917-29.
54. Alter MJ, Seeff LB, Bacon BR, Thomas DL, Rigsby MO, Di Bisceglie AM. Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. *Ann Intern Med*

- 2004;141(9):715-7.
55. Vergani D, Mieli-Vergani G. Autoimmune hepatitis and sclerosing cholangitis. *Autoimmunity* 2004;37(4):329-32.
56. Lo Re V 3rd, Kostman JR. Anemia during treatment of hepatitis C in HIV-infected patients. *AIDS Read* 2004;14(10):555-7, 562, 565-71.
57. Liang TJ, Heller T. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. *Gastroenterology* 2004;127(5 Suppl 1):S62-71.
58. Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. *Gastroenterology* 2004;127(5 Suppl 1):S56-61.
59. Lok AS. Prevention of hepatitis B virus-related hepatocellular carcinoma. *Gastroenterology* 2004;127(5 Suppl 1):S303-9.
60. Heathcote EJ. Prevention of hepatitis C virus-related hepatocellular carcinoma. *Gastroenterology* 2004;127(5 Suppl 1):S294-302.
61. Alberti A, Benvegna L, Boccato S, Ferrari A, Sebastiani G. Natural history of initially mild chronic hepatitis C. *Dig Liver Dis* 2004;36(10):646-54.
62. Stevenson L, Faucher Y, Hewlett S, Klemm K, Nelson D. Chronic hepatitis C virus and the Hispanic community: cultural factors impacting care. *Gastroenterol Nurs* 2004;27(5):230-8.
63. Alvarez DF, Latorre JS. Hepatitis C virus and HIV coinfection: clinical management and new strategies. *AIDS Read* 2004;14(10 Suppl):S16-21.
64. Shoukry NH, Cawthon AG, Walker CM. Cell-mediated immunity and the outcome of hepatitis C virus infection. *Annu Rev Microbiol.* 2004;58:391-424.
65. Simmonds P. Genetic diversity and evolution of hepatitis C virus--15 years on. *J Gen Virol* 2004;85(Pt 11):3173-88.
66. Abdo AA, Lee SS. Management of hepatitis C virus genotype 4. *J Gastroenterol Hepatol* 2004;19(11):1233-9.
67. Karayiannis P. Current therapies for chronic hepatitis B virus infection. *Expert Rev Anti Infect Ther* 2004;2(5):745-60.
68. O'Leary J, Chung RT. New antiviral therapies for hepatitis C. *Expert Rev Anti Infect Ther* 2004;2(2):235-43.
69. Ranger-Rogez S, Denis F. Hepatitis B mother-to-child transmission. *Expert Rev Anti Infect Ther* 2004;2(1):133-45.
70. Durantel D, Escuret V, Zoulim F. Current and emerging therapeutic approaches to hepatitis C infection. *Expert Rev Anti Infect Ther* 2003;1(3):441-54.
71. Vyas JJ, Brown RS, Gaglio PJ. Hepatitis C-HIV coinfection: current and future therapy. *Expert Rev Anti Infect Ther* 2003;1(3):433-9.
72. Han SH. Extrahepatic manifestations of chronic hepatitis B. *Clin Liver Dis* 2004;8(2):403-18.
73. Broderick A, Jonas MM. Management of hepatitis B in children. *Clin Liver Dis* 2004;8(2):387-401.
74. Cooksley WG. Treatment of hepatitis B with interferon and combination therapy. *Clin Liver Dis* 2004;8(2):353-70.
75. Wai CT, Fontana RJ. Clinical significance of hepatitis B virus genotypes, variants, and mutants. *Clin Liver Dis* 2004;8(2):321-52, vi.
76. Lee JY, Locarnini S. Hepatitis B virus: pathogenesis, viral intermediates, and viral replication. *Clin Liver Dis* 2004;8(2):301-20.
77. Yu AS, Cheung RC, Keeffe EB. Hepatitis B vaccines. *Clin Liver Dis* 2004;8(2):283-300.
78. Servoss JC, Friedman LS. Serologic and molecular diagnosis of hepatitis B virus. *Clin Liver Dis* 2004;8(2):267-81.
79. Tran TT, Martin P. Hepatitis B: epidemiology and natural history. *Clin Liver Dis* 2004;8(2):255-66.
80. Curry MP. Hepatitis B and hepatitis C viruses in liver transplantation. *Transplantation* 2004;78(7):955-63.
81. Eisenbach C, Gehrke SG, Stremmel W. Iron, the HFE gene, and hepatitis C. *Clin Liver Dis* 2004;8(4):775-85, vii-viii.
82. Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. *Antiviral Res* 2004;64(1):1-15.
83. Mast EE. Mother-to-infant hepatitis C virus transmission and breastfeeding. *Adv Exp Med Biol* 2004;554:211-6.
84. Ito K, Mitchell DG. Imaging diagnosis of cirrhosis and chronic hepatitis. *Intervirolgy* 2004;47(3-5):134-43.

85. Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. *Liver Transpl* 2004;10(10 Suppl 2):S74-85.
86. Fung J, Eghtesad B, Patel-Tom K, DeVera M, Chapman H, Ragni M. Liver transplantation in patients with HIV infection. *Liver Transpl* 2004;10(10 Suppl 2):S39-53.
87. Fung SK, Lok AS. Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? *Hepatology* 2004;40(4):790-2.
88. Hu J, Nguyen D. Therapy for chronic hepatitis B: the earlier, the better? *Trends Microbiol* 2004;12(10):431-3.
89. Nagao Y, Sata M. Hepatitis C virus and lichen planus. *J Gastroenterol Hepatol* 2004;19(10):1101-13.
90. Stapleton JT, Williams CF, Xiang J. GB virus type C: a beneficial infection? *Clin J Microbiol* 2004;42(9):3915-9.
91. Lim JK, Imperial JC, Keeffe EB. Retreatment of chronic hepatitis C virus infection. *Rev Gastroenterol Disord* 2004;4(3):97-103.
92. Dillon JF. Hepatitis C: What is the best treatment? *J Viral Hepat* 2004;11 Suppl 1:23-7.
93. Main J, Thomas H. Hepatitis C: How should we manage the patient? *J Viral Hepat* 2004;11 Suppl 1:19-22.
94. Goldberg D, Anderson E. Hepatitis C: who is at risk and how do we identify them? *J Viral Hepat* 2004;11 Suppl 1:12-8.
95. Delahooke TE. Hepatitis C: What is the nature of the problem? *J Viral Hepat* 2004;11 Suppl 1:5-11.
96. Thomson EC, Main J. Advances in hepatitis B and C. *Curr Opin Infect Dis* 2004;17(5):449-59.
97. Skoretz S, Zaniewski G, Goedhuis NJ. Hepatitis C virus transmission in the prison/inmate population. *Can Commun Dis Rep* 2004;30(16):141-8.
98. Tan SL, He Y, Huang Y, Gale M Jr. Strategies for hepatitis C therapeutic intervention: now and next. *Curr Opin Pharmacol* 2004;4(5):465-70.
99. Safdar K, Schiff ER. Alcohol and hepatitis C. *Semin Liver Dis* 2004;24(3):305-15.
100. Foster GR. Past, present, and future hepatitis C treatments. *Semin Liver Dis* 2004;24 Suppl 2:97-104.
101. Charlton M, Wiesner R. Natural history and management of hepatitis C infection after liver transplantation. *Semin Liver Dis* 2004;24 Suppl 2:79-88.
102. Poynard T. Treatment of hepatitis C virus: the first decade. *Semin Liver Dis*. 2004;24 Suppl 2:19-24.
103. Ferreira-Gonzalez A, Shiffman ML. Use of diagnostic testing for managing hepatitis C virus infection. *Semin Liver Dis* 2004;24 Suppl 2:9-18.
104. Afdhal NH. The natural history of hepatitis C. *Semin Liver Dis* 2004;24 Suppl 2:3-8.
105. Kanto T, Hayashi N. Measuring immunity in viral hepatitis. *J Gastroenterol* 2004;39(8):709-16.
106. Ghany MG, Doo EC. Management of chronic hepatitis B. *Gastroenterol Clin North Am* 2004;33(3):563-79, ix.
107. Ahmed F, Jacobson IM. Treatment of relapsers after combination therapy for chronic hepatitis C. *Gastroenterol Clin North Am* 2004;33(3):513-26, viii.
108. Oh S, Afdhal NH. Antiviral therapy for treatment naive patients with hepatitis C virus. *Gastroenterol Clin North Am* 2004;33(3):497-511, viii.
109. Dove LM. A general approach to the management of chronic hepatitis C. *Gastroenterol Clin North Am* 2004;33(3):463-77, vii.
110. Williams J. Guidelines to determine who should be tested for hepatitis C. *Nurs Times* 2004;100(28):28-9.
111. Frank RE. Autoimmune hepatitis. *J Insur Med*. 2002;34(2):120-4.
112. Berenguer M. Viral hepatitis B, C and D. *Acta Gastroenterol Belg* 2004;67(2):197-205.
113. Moreno R, Berenguer M. Hepatitis C and liver transplantation. *Ann Hepatol* 2002;1(3):129-35.
114. Camma C, Di Bona D, Craxi A. The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach. *Curr Pharm Des* 2004; 10(17):2123-30.
115. Santantonio T. Treatment of acute hepatitis C. *Curr Pharm Des* 2004; 10(17):2077-80.
116. Brunetto MR, Bonino F. Treatment of chronic hepatitis B: from research to clinical practice via the consensus conferences. *Curr Pharm Des* 2004; 10(17):2063-75.
117. Suskind DL, Rosenthal P. Chronic viral hepatitis. *Adolesc Med Clin* 2004; 15(1):145-58, x-xi.

118. Wang L, Zhuang H. Hepatitis E: an overview and recent advances in vaccine research. *World J Gastroenterol* 2004;10(15):2157-62.
119. Kelly D. Viral hepatitis in children. *Adv Exp Med Biol* 2004;549:83-90.
120. Heathcote J, Ramji A. When to treat patients with chronic hepatitis C. *Curr Gastroenterol Rep* 2004;6(4):261-3.
121. Rodriguez-Luna H, Douglas DD. Natural history of hepatitis C following liver transplantation. *Curr Opin Infect Dis* 2004;17(4):363-71.
122. Worm HC, Wirnsberger G. Hepatitis E vaccines: progress and prospects. *Drugs* 2004;64(14):1517-31.
123. D'Souza R, Foster GR. Diagnosis and treatment of chronic hepatitis B. *J R Soc Med* 2004;97(7):318-21.
124. Teoh NC, Farrell GC. Management of chronic hepatitis C virus infection: a new era of disease control. *Intern Med J* 2004;34(6):324-37.
125. Vrolijk JM, de Knecht RJ, Veldt BJ, Orlent H, Schalm SW. The treatment of hepatitis C: history, presence and future. *Neth J Med* 2004;62(3):76-82.
3. Vinelli E, Visona K, Nuila L. Prevalencia de anticuerpos contra el virus de la hepatitis c y otros marcadores virales en donantes de sangre voluntarios de la Cruz Roja Hondureña. *Rev Med Hondur* 1990; 58(3):166-9.
4. Durón Martínez RA, Dala Sierra E. Enfoque actual de la hepatitis viral B (HBV). *Rev Med Hondur* 1988;1(57):48-55.4.
5. Zúniga Alemán GA, Ordóñez Tercero BA. Hepatitis en el IHSS. *Rev Med Hondur* 1978; 2(46):49-52.

OTRAS REVISTAS Y DOCUMENTOS

1. Honduras. Secretaría de Salud. Programa Ampliado de Inmunizaciones. Vigilancia de la hepatitis B en Honduras. Tegucigalpa; PAI; 1997. Centr. Docum. OPS/OMS-Honduras.
2. Godoy Romero A, Fernández J. Normas técnicas para la prevención de transmisión de enfermedades infectocontagiosas en los servicios de salud. Tegucigalpa; Honduras. Secretaría de Salud. Departamento ETS/SIDA; dic. 1997. Centr.Docum.OPS/OMS-Honduras.
3. Grinspan Korper S, Grave de Peralta LG. Seroprevalencia de hepatitis B y C en donadores de sangre. *Med Clín (Honduras)* 1992; 1 (3/4):120-2.

SITIOS WEB

1. <http://www.cdc.gov/ncidod/diseases/hepatitis/a/>
2. <http://www.cdc.gov/ncidod/diseases/hepatitis/b/>
3. <http://www.cdc.gov/ncidod/diseases/hepatitis/c/>
4. <http://www.cdc.gov/ncidod/diseases/hepatitis/d/>
5. <http://www.cdc.gov/ncidod/diseases/hepatitis/e/>
6. <http://www.cdc.gov/nip/vaccine/hep/default.htm>
7. <http://www.who.int/csr/disease/hepatitis/en/>
8. <http://www.who.int/vaccines/en/hepatitisa>
9. <http://www.who.int/vaccines/en/hepatitisb>
10. <http://w3.whosea.org/bct/microbio/ch25.htm>

REVISTA MEDICA HONDUREÑA

1. Lorenzana de Rivera I, Lara C, Sánchez L. Prevalencia de marcadores de hepatitis b y c en diferentes grupos poblacionales de la Región Metropolitana de Honduras. *Rev Med Hondur* 1997;65(1):9-16.
2. Elvir Mairena JR. Radicales libres, alcoholismo y daño hepático. *Rev Med Hondur* 1994; 62(2):76-82.

TESIS PARA OPTAR AL GRADO DE DOCTOR EN MEDICINA

1. Ortiz Bonilla S. Hepatitis alcohólica. Estudio retrospectivo en pacientes egresados del Hospital Escuela durante el período Enero 1983 a Diciembre 1987. HN1.1/616.861*O77, 1988.
2. Meléndez Colindres VM. Aspectos epidemiológicos de la hepatitis viral tipo B en Villanueva, Cortés. HN1.1/616.3623*M51, 1983.
3. Alvarado Matute GN, Arita Mejia GC. Factores que condicionan la hepatitis viral en el Distrito Central y tipo predominante. HN1.1/616.3623*A47f, 1977.
4. Madrid Zelaya GR. Hepatitis por virus. HN1.1/616.362364*M18, 1960.